SLG 200
Alternative Names: SLG-200Latest Information Update: 29 May 2024
At a glance
- Originator SELAGINE
- Class Antibacterials; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 15 May 2024 Preclinical trials in Ocular inflammation in USA (Ophthalmic) (SELAGINE pipeline; May 2024)
- 15 May 2024 SELAGINE plans phase-I trial for Bacterial infections(Opthalmic) (SELAGINE pipeline; May 2024)